Abstract: A minimally invasive magnetic vocal fold manipulator system and method is disclosed. Namely, a magnetic vocal fold manipulator system is provided that includes a magnetics-based thyroid cartilage implant, a magnetics-based arytenoid cartilage implant, and an implant introducer device. Additionally, a method is provided of using the minimally invasive magnetic vocal fold manipulator system for performing lateralization and/or medialization of the vocal cord.

Abstract: Self-adaptive systems, uses of the systems, and methods for adapting one or more properties of a material are disclosed.

Abstract: Provided is a method, device, and computer-readable medium for controlling a robot graphic user interface (“RGUI”) on a mobile device. The method can include determining a distance, a position, or both of the mobile device with respect to a first robot; and causing, by a processor, a first RGUI to be displayed on a display of the mobile device based on the determining.

Abstract: The present invention has developed methods and compositions utilizing the cell surface CD107a (LAMP-1) as a marker that divides bone-forming and fat-forming progenitor/stem cells within human adipose tissue. The present invention is able to partition stromal progenitors for improved bone and soft tissue engineering and therapies.

Abstract: A device for magnetic resonance artifact correction includes an array of shim coils sequentially arranged to receive a current, such that a first force arising from an interaction of a magnetic field with the current in one shim coil is balanced by a second force on the array arising from interactions of the magnetic field with the current in other shim coils when the array is operated within an imaging volume of a magnetic resonance system. The device includes a frame of non-ferromagnetic material, to provide selectable positioning of the array, and a signal processor to use a measurement of a magnetic field inhomogeneity within a region of the imaging volume, to determine a current for the shim coils and coordinates for positioning the array within the imaging volume, such that applying the current to the array at the coordinates generates a correction field to reduce the magnetic field inhomogeneity.

Abstract: A microcapsule includes an oxime-based polymerization product of two or more monomers and a payload. The payload may be encapsulated within the microcapsule. The oxime-based polymerization products may include an oxime-based monomer and an isocyanate-based monomer. Methods of making such microcapsules and methods of delivering a payload to a target using such microcapsules are provided.

Abstract: A submersible vehicle may include a propulsion assembly, a pressure vessel, and a floodable actuator vessel. A bulkhead may seal a pressure shell of the pressure vessel to prevent fluid intrusion into an interior cargo compartment of the pressure shell when the submersible vehicle is submersed into a fluid. The floodable actuator vessel may be coupled to the pressure vessel and may include a floodable shell and a plurality of actuators. The floodable shell may include a plurality of flood openings configured to permit fluid intrusion into an interior flood space of the floodable shell when the submersible vehicle is submersed into a fluid. Each actuator may be disposed within the interior flood space and affixed to an interior surface of the floodable shell at an actuator opening through which an external fin is actuated to maneuver the submersible vehicle in coordination with the propulsion assembly.

Abstract: Provided is a functional, low-profile intercranial device (LID). The LID includes a base portion; at least one cavity associated with the base portion and configured to accept at least one functional component; and at least one conduit having a first end in communication with the at least one cavity. The at least one functional component includes a medicinal, electronic, or optic therapeutic. The at least one conduit is configured to accept the medicinal therapeutic and a second end configured to dispense the therapeutic.

Abstract: Provided herein are methods of determining a cognitive load of a sensorized device user in certain aspects. Provided herein are also methods of adjusting an interface between a user and a sensorized device in some aspects. Related devices, systems, and computer program products are also provided.

Abstract: An insect trap analysis system may detect an insect specimen on a trap mechanism of an insect trap. The insect trap analysis system may control, based on detecting the insect specimen on the trap mechanism, one or more mechanical devices to: adjust a position of the insect specimen relative to a position of an image capture device associated with the insect trap, or adjust the position of the image capture device relative to the position of the insect specimen. The insect trap analysis system may cause, while controlling the one or more mechanical devices to adjust the position of the image capture device or the position of the insect specimen, the image capture device to capture a plurality of images of the insect specimen from a plurality of different angles relative to the insect specimen, and may perform an action associated with the plurality of images.

Abstract: The identification of mutations that are present in a small fraction of DNA templates is essential for progress in several areas of biomedical research. Though massively parallel sequencing instruments are in principle well-suited to this task, the error rates in such instruments are generally too high to allow confident identification of rare variants. We here describe an approach that can substantially increase the sensitivity of massively parallel sequencing instruments for this purpose. One example of this approach, called “Safe-SeqS” for (Safe-Sequencing System) includes (i) assignment of a unique identifier (UID) to each template molecule; (ii) amplification of each uniquely tagged template molecule to create UID-families; and (iii) redundant sequencing of the amplification products. PCR fragments with the same UID are truly mutant (“super-mutants”) if ?95% of them contain the identical mutation.

Abstract: The present invention relates to the field of virology. More specifically, the present invention provides methods and compositions useful for prevention and treatment of human cytomegalovirus (CMV). In one embodiment, a pharmaceutical composition comprises (a) emetine or a derivative thereof; (b) a human cytomegalovirus (HCMV) drug; and (c) a pharmaceutically acceptable carrier. In certain embodiments, the pharmaceutical composition further comprises an adjuvant. In a specific embodiment, the HCMV drug is ganciclovir. In such embodiments, emetine is present at about 1/10 to about 1/100 the normal dosage for amebiasis.

Abstract: A sensing fretboard for stringed instruments is described herein with respect to a guitar. The present invention includes custom frets and a modular sensing array that can be incorporated into a fretboard and coupled to the guitar. By measuring the dynamic forces applied by the players on the frets and strings of the guitar, musicians can be warned in real time during practice, when their grip is too strong, and to help musicians learn and recover from injuries.

Abstract: The present invention describes an integrated apparatus that enables identification of migratory cells directly from a specimen. The apparatus only requires a small number of cells to perform an assay and includes novel topographic features which can reliably differentiate between migratory and non-migratory cell populations in a sample. Both the spontaneous and chemotactic migration of cancer cells may be measured to distinguish between subpopulations within a tumor sample. The migratory cells identified using the apparatus and methods of the present invention may be separated and further analyzed to distinguish factors promoting metastasis within the population. Cells in the apparatus can be treated with chemotherapeutic or other agents to determine drug strategies to most strongly inhibit migration. The use of optically transparent materials in some embodiments allows a wide range of imaging techniques to be used for in situ imaging of migratory and non migratory cells in the apparatus.

Abstract: An adenovirus or adenoviral vector is described that includes a non-native nucleotide sequence capable of expressing a chimeric protein comprising an N-terminal nucleotide binding domain of transactivation response element DNA-binding protein (TDP-43), a C-terminal domain derived from a splicing repressor, and an autoregulatory element. Methods of using the adenovirus or adenoviral vector to treat degenerative diseases such as inclusion body myocytosis, amyotrophic lateral sclerosis, and frontotemporal dementia are also described.

Abstract: Techniques for label-free determination of a value of at least one blood property are presented. The techniques may utilize a device that includes an optical objective including at least one lens, at least a first light source situated so as to provide light to a body part at a location that is off-center from a central axis of the objective, at least a first electronic detector situated to receive light gathered by the optical objective and generate image data, at least one electronic processor communicatively coupled to the first electronic detector, the at least one electronic processor configured to determine the value of the at least one blood property based at least in part on the image data, and an output interface communicatively coupled to the at least one electronic processor and configured to provide the value of the at least one blood property.

Abstract: Glutamine antagonists and their use for treating oncological, immunological, and neurological diseases are disclosed. Also disclosed are methods for treating an oncological, immunological, infectious or neurological disease or disorder, the method comprising administering to a subject in need of treatment thereof a therapeutically effective amount of a glutamine antagonist of the disclosure or the pharmaceutical composition thereof. Also disclosed are methods of enhancing the effects of an immune checkpoint inhibitor, enabling a subject to respond to an immune checkpoint inhibitor, or enabling the toxicity or the dose or number of treatments with an immune checkpoint inhibitor to be reduced, comprising administering to a subject in need of treatment thereof a therapeutically effective amount of a glutamine antagonist of the disclosure or the pharmaceutical composition thereof, and an immune checkpoint inhibitor.

Abstract: A method, a system, a device, and a computer program produce for photon detection is disclosed. The method includes receiving, by a plurality of anodes, a photon via one or more of the plurality of anodes; measuring respective voltages of the photon at each of the plurality of anodes; counting incidents in which the photon is detected by more than one of the plurality of anodes based on the measuring; and outputting information regarding a counted number of incidents in which the photon is detected by more than one of the plurality of anodes, wherein the information regarding the courted number of incidents in which the photon is detected by more than one of the plurality of anodes is used as part of a production of an image associated with the received photon.

Abstract: Small molecule inhibitors of neutral sphingomyelinase 2 (nSMase2) and their use for treating neurodegenerative diseases, such as, neurodegenerative diseases associated with high levels of ceramide, including, but not limited to Alzheimer's disease (AD), HIV-associated neurocognitive disorder (HAND), multiple sclerosis (MS), and amyotrophic lateral sclerosis (ALS), and, in other aspects, for treating cancer or HIV-1, are provided.

Abstract: Devices and methods for delivering oxygen and other therapeutic gases to a target, such as a tissue, a tissue-engineered construct, and a wound, in a controlled and sustained manner are disclosed.